MA31180B1 - Procede de synthese de composes 2-aminothiazole comme inhibiteurs de kinase - Google Patents

Procede de synthese de composes 2-aminothiazole comme inhibiteurs de kinase

Info

Publication number
MA31180B1
MA31180B1 MA32161A MA32161A MA31180B1 MA 31180 B1 MA31180 B1 MA 31180B1 MA 32161 A MA32161 A MA 32161A MA 32161 A MA32161 A MA 32161A MA 31180 B1 MA31180 B1 MA 31180B1
Authority
MA
Morocco
Prior art keywords
synthesis
kinase inhibitors
group
inhibitors
aminothiazole compounds
Prior art date
Application number
MA32161A
Other languages
Arabic (ar)
English (en)
Inventor
Alain Moussy
Philippe Reginault
François Bellamy
Anne Lermet
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Publication of MA31180B1 publication Critical patent/MA31180B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Cette invention se rapporte à un procédé industriel permettant de préparer des composés pharmaceutiques de formule (i) qui sont utilisés comme inhibiteurs de certaines tyrosine kinases et plus particulièrement comme inhibiteurs de c-kit et de bcr-abl. Les groupes r1 et r2, identiques ou différents, représentent chacun un atome d'hydrogène, un atome d'halogène, un groupe alkyle, alcoxy, trifluorométhyle, amino, alkylamino, dialkylamino, un groupe de solubilisation; m vaut de 0 à 5 et n vaut de 0 à 4; le groupe r3 représente un groupe aryle ou hétéroaryle comme décrit dans les revendications.
MA32161A 2007-02-13 2009-08-11 Procede de synthese de composes 2-aminothiazole comme inhibiteurs de kinase MA31180B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88958707P 2007-02-13 2007-02-13
PCT/EP2008/051704 WO2008098949A2 (fr) 2007-02-13 2008-02-13 Procédé de synthèse de composés 2-aminothiazole comme inhibiteurs de kinase

Publications (1)

Publication Number Publication Date
MA31180B1 true MA31180B1 (fr) 2010-02-01

Family

ID=39332208

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32161A MA31180B1 (fr) 2007-02-13 2009-08-11 Procede de synthese de composes 2-aminothiazole comme inhibiteurs de kinase

Country Status (23)

Country Link
US (3) US8153792B2 (fr)
EP (2) EP2366703B1 (fr)
JP (2) JP5568312B2 (fr)
KR (1) KR20090110851A (fr)
CN (2) CN103342701B (fr)
AR (1) AR065337A1 (fr)
AT (1) ATE515506T1 (fr)
AU (1) AU2008214679A1 (fr)
BR (1) BRPI0807626B1 (fr)
CA (2) CA2677586C (fr)
ES (2) ES2369617T3 (fr)
HR (2) HRP20110709T1 (fr)
IL (1) IL200320A0 (fr)
MA (1) MA31180B1 (fr)
MX (1) MX2009008665A (fr)
NZ (1) NZ578944A (fr)
PL (2) PL2366703T3 (fr)
RU (2) RU2456285C2 (fr)
SI (2) SI2366703T1 (fr)
TN (1) TN2009000342A1 (fr)
TW (1) TWI406862B (fr)
WO (1) WO2008098949A2 (fr)
ZA (1) ZA200905981B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05001277A (es) 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
US20120302577A1 (en) 2010-01-28 2012-11-29 Ab Science Treatment of gist with masitinib
TW201130830A (en) 2010-02-01 2011-09-16 Ab Science Combined treatment of pancreatic cancer with gemcitabine and masitinib
AR080380A1 (es) 2010-03-09 2012-04-04 Ab Science Tratamiento de la demencia tipo alzheimer con masitinib
TW201204360A (en) 2010-04-20 2012-02-01 Ab Science Treatment of multiple sclerosis with MASITINIB
WO2011151372A1 (fr) 2010-06-02 2011-12-08 Ab Science Traitement de l'arthrite rhumatoïde par du masitinib
US10045978B2 (en) 2010-11-05 2018-08-14 Ab Science Treatment of mastocytosis with masitinib
WO2012059526A1 (fr) 2010-11-05 2012-05-10 Ab Science Traitement de la mastocytose par le masitinib
WO2012104402A1 (fr) * 2011-02-04 2012-08-09 Ab Science Traitement de l'asthme sévère persistant avec le masitinib
US20140051662A1 (en) 2011-04-08 2014-02-20 Ab Science Treatment of multiple myeloma with masitinib
AU2013326463B2 (en) 2012-10-04 2018-01-18 Ab Science Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors
TW201605449A (zh) 2013-12-02 2016-02-16 Ａｂ化學公司 馬賽替尼治療結腸直腸癌的用途
EP2886543A1 (fr) 2013-12-18 2015-06-24 Sandoz Ag Forme cristalline de masitinibe
WO2015185958A1 (fr) 2014-06-02 2015-12-10 Ab Science Utilisation d'un inhibiteur de l'activité kinase, en particulier le masitinib, pour le traitement du cancer de la prostate
CN105585556A (zh) * 2014-11-13 2016-05-18 连云港杰瑞药业有限公司 一种伊马替尼的合成方法
WO2017016512A1 (fr) * 2015-07-29 2017-02-02 苏州晶云药物科技有限公司 Nouvelle forme cristalline du mésylate de masitinib et son procédé de préparation
CA3000894A1 (fr) 2015-10-05 2017-04-13 Ab Science Traitement de la mastocytose systemique grave par le masitinib
EA038531B1 (ru) 2016-03-25 2021-09-10 Аб Сьянс Способ лечения амиотрофного латерального склероза, применение фармацевтической композиции, содержащей мазитиниб
WO2018177854A1 (fr) 2017-03-31 2018-10-04 Sandoz Ag Forme cristalline de masitinib
US10696638B2 (en) 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
EP4061371B1 (fr) 2019-11-22 2025-02-19 AB Science Masitinib pour le traitement de la drépanocytose
EP3831384A1 (fr) 2019-12-02 2021-06-09 AB Science Utilisation de masitinib pour le traitement de l'asthme éosinophile
AU2021223710A1 (en) 2020-02-20 2022-07-28 Ab Science Masitinib for the treatment of a multiple sclerosis patient subpopulation
WO2021205029A1 (fr) 2020-04-10 2021-10-14 Ab Science Utilisation de masitinib pour le traitement de la maladie à coronavirus 2019 (covid-19)
US20240058328A1 (en) 2020-12-16 2024-02-22 Ab Science Masitinib for the treatment of alzheimer's disease
ES2963706T3 (es) 2021-05-17 2024-04-01 Ab Science Masitinib para el tratamiento del cáncer de próstata resistente a la castración
CN115850258B (zh) * 2022-12-27 2024-09-24 东北林业大学 一种马赛替尼的合成方法
WO2025264860A2 (fr) 2024-06-18 2025-12-26 Yale University Méthodes de traitement d'une maladie des voies respiratoires post-covid

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3299087A (en) * 1961-04-24 1967-01-17 Geigy Chem Corp Nu, nu'-bis-(thiazolyl)-phenylenediamines
US5932576A (en) * 1997-05-22 1999-08-03 G. D. Searle & Company 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
CN1158269C (zh) * 1997-10-27 2004-07-21 阿古龙制药公司 作为cdk抑制剂的取代的4-氨基-噻唑-2-基化合物
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
MXPA02002559A (es) * 1999-09-10 2002-07-30 Merck & Co Inc Inhibidores de tirosina cinasa.
US20030091974A1 (en) 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
JP2005503361A (ja) 2001-06-29 2005-02-03 アブ サイエンス 肥満細胞症治療のための強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤の使用
WO2003003006A2 (fr) 2001-06-29 2003-01-09 Ab Science Nouveaux inhibiteurs selectifs puissants et non toxiques de c-kit
DE60227709D1 (de) 2001-06-29 2008-08-28 Ab Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
PT1401416E (pt) 2001-06-29 2007-02-28 Ab Science Utilização de inibidores de c-kit para tratar doenças inflamatórias intestinais (dii)
WO2003002107A2 (fr) 2001-06-29 2003-01-09 Ab Science Utilisation d'inhibiteurs de tyrosine kinase dans le traitement de la sclerose en plaques
ES2274993T3 (es) 2001-06-29 2007-06-01 Ab Science Utilizacion de inhibidores de tirosina cinasa para el tratamiento de enfermedades alergicas.
JP2004530730A (ja) 2001-06-29 2004-10-07 アブ サイエンス 腫瘍の血管新生を治療するための強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤の使用法
WO2003002105A2 (fr) 2001-06-29 2003-01-09 Ab Science Utilisation d'inhibiteurs de la tyrosine kinase dans le traitement de la perte osseuse
ATE330608T1 (de) 2001-06-29 2006-07-15 Ab Science Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
EP1461032B1 (fr) 2001-09-20 2008-07-16 AB Science Utilisation d'inhibiteurs de la c-kit pour stimuler la pousse des cheveux
JP2005511596A (ja) 2001-09-20 2005-04-28 アブ サイエンス ヒトの皮膚を白くし、且つメラノサイト機能不全関連疾病を治療するためのチロシンキナーゼ阻害剤の使用方法
DE60225590T2 (de) 2001-09-20 2008-09-25 Ab Science C-kithemmer zur behandlung von bakteriellen infektionen
PT1478380E (pt) 2002-02-27 2006-12-29 Ab Science Utilização de inibidores de tirosina-cinases para tratar doenças do snc
ATE408407T1 (de) 2002-02-27 2008-10-15 Ab Science Verwendung von tyrosinkinase-hemmern zur behandlung von erkrankungen im zusammenhang mit substanzgebrauch
CA2486530A1 (fr) * 2002-05-29 2003-12-11 Amgen Inc. Derives 2-oxo-1,3,4-trihydroquinazolinyle utilises dans le traitement de troubles associes a la proliferation de cellules
MXPA05001277A (es) 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
SE0202462D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel use
WO2004072068A1 (fr) * 2003-02-10 2004-08-26 Amgen Inc. Ligands du recepteur vanilloide et leur utilisation dans des traitements
ATE393243T1 (de) 2003-02-27 2008-05-15 Ab Science Diagnostisches verfahren der mastozytose
FR2854158B1 (fr) * 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
AU2004260689B8 (en) * 2003-07-29 2008-05-15 Irm Llc Compounds and compositions as protein kinase inhibitors
DE602004013792D1 (de) 2003-08-15 2008-06-26 Ab Science Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
US7363881B2 (en) 2003-11-06 2008-04-29 Nova-Tech Engineering, Inc. Beak treatment with tongue protection
WO2005063709A1 (fr) 2003-12-25 2005-07-14 Nippon Shinyaku Co., Ltd. Derive d'amide et medicament
US7650848B2 (en) * 2004-02-17 2010-01-26 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
WO2005115385A1 (fr) * 2004-05-24 2005-12-08 Ab Science Utilisation d'inhibiteurs de c-kit pour le traitement de l'acne
TW200702876A (en) * 2005-07-04 2007-01-16 Avermedia Tech Inc Projector device capable of sychronously encoding audio and video to become AV sychronous paly file

Also Published As

Publication number Publication date
NZ578944A (en) 2011-03-31
RU2456285C2 (ru) 2012-07-20
CN101657446B (zh) 2013-05-15
CN101657446A (zh) 2010-02-24
ZA200905981B (en) 2010-11-24
ATE515506T1 (de) 2011-07-15
SI2366703T1 (sl) 2014-10-30
ES2522169T3 (es) 2014-11-13
EP2366703B1 (fr) 2014-07-30
RU2491286C1 (ru) 2013-08-27
WO2008098949A2 (fr) 2008-08-21
TWI406862B (zh) 2013-09-01
US8492545B2 (en) 2013-07-23
ES2369617T3 (es) 2011-12-02
CA2677586C (fr) 2017-07-25
HRP20110709T1 (hr) 2011-11-30
EP2118099B1 (fr) 2011-07-06
JP5784073B2 (ja) 2015-09-24
AU2008214679A1 (en) 2008-08-21
CA2970628A1 (fr) 2008-08-21
US8153792B2 (en) 2012-04-10
BRPI0807626A2 (pt) 2014-11-25
RU2009132186A (ru) 2011-03-20
JP5568312B2 (ja) 2014-08-06
EP2366703A1 (fr) 2011-09-21
PL2366703T3 (pl) 2015-02-27
EP2118099A2 (fr) 2009-11-18
WO2008098949A3 (fr) 2008-10-02
SI2118099T1 (sl) 2011-11-30
CA2970628C (fr) 2019-08-27
BRPI0807626B1 (pt) 2022-03-03
TN2009000342A1 (en) 2010-12-31
JP2013177437A (ja) 2013-09-09
US8940894B2 (en) 2015-01-27
CN103342701A (zh) 2013-10-09
KR20090110851A (ko) 2009-10-22
TW200848419A (en) 2008-12-16
HRP20140986T1 (hr) 2014-11-21
PL2118099T3 (pl) 2011-12-30
MX2009008665A (es) 2009-08-21
AR065337A1 (es) 2009-06-03
US20130289045A1 (en) 2013-10-31
CN103342701B (zh) 2016-09-21
CA2677586A1 (fr) 2008-08-21
JP2010518141A (ja) 2010-05-27
IL200320A0 (en) 2010-04-29
US20100121063A1 (en) 2010-05-13
US20120196871A1 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
TN2009000342A1 (en) Process for the synthesis of 2- aminothiazole compounds as kinase inhibitors
JP7331212B2 (ja) フェニル－２－ヒドロキシ－アセチルアミノ－２－メチル－フェニル化合物
JP5897590B2 (ja) キナゾリンカルボキサミドアゼチジン
IN2014DN06567A (fr)
CY1120169T1 (el) Παραγωγο αμιδιου και φαρμακο
MY141229A (en) Piperidine-benzenesulfonamide derivatives
MA28076A1 (fr) Derives de 2,4-di(hetero)-arylamino-pyrimidine comme inhibiteurs des kinases zap-70 et/ou syk
ZA200309005B (en) New indole derivatives with 5-HT6 receptor affinity.
Raj et al. Discovery of highly selective 7-chloroquinoline-thiohydantoins with potent antimalarial activity
MA30076B1 (fr) Carbonylaminopyrrolopyrazoles servant de puissants inhibiteurs de kinases.
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
BR112013001341A2 (pt) compostos de pirimidina como inibidores de proteínas quinases ikk épsilon e/ou tbk-1, processo para a preparação dos mesmos e suas composições farmacêuticas
DE602007009085D1 (de) Neues verfahren zur synthese von 2-aminooxazolverbindungen
MA30311B1 (fr) Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2004004730A3 (fr) Composes pharmaceutiques
MA31674B1 (fr) Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique
RU2012103460A (ru) НОВЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРО-1Н-ИМИДАЗО{1,2-a}ПИРИМИДИН-5-ОНА, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ В ФАРМАЦИИ
MA33320B1 (fr) Derives de rifamycine
JP6694531B2 (ja) 抗腫瘍効果を有するイミダゾオキサゾール誘導体、及びそれを含む薬学的組成物
CN117865886B (zh) 一种n-(喹啉-8-基)喹啉-8-磺酰胺类化合物及其应用
EP1838322A2 (fr) Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 et pour le traitement du cancer
ATE480239T1 (de) Angiogeneseinhibitoren
MA27931A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4
NO20062791L (no) 1-benzyl-5-piperazin-1-yl-34 4 dihydro-lH-kinazolin-2-on derivater og de respektive 1H-benzo(1,2,6) tiadiazin-2,2-dioksid og 1, 4-dihydro-benzo (D) (1,3)oksazin-2-on derivater som modulatorer av 5-hydroksytryptamin reseptor (5-HT) for behandling av sykdom